{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:22:01Z","timestamp":1790166121425,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The study was funded by Sanofi Pasteur"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zika virus (ZIKV) is an emerging mosquito-borne pathogen representing a global health concern. It has been linked to fetal microcephaly and other birth defects and neurological disorders in adults. Sanofi Pasteur has engaged in the development of an inactivated ZIKV vaccine, as well as a live chimeric vaccine candidate ChimeriVax-Zika (CYZ) that could become a preferred vaccine depending on future ZIKV epidemiology. This report focuses on the CYZ candidate that was constructed by replacing the pre-membrane and envelope (prM-E) genes in the genome of live attenuated yellow fever 17D vaccine virus (YF 17D) with those from ZIKV yielding a viable CYZ chimeric virus. The replication rate of CYZ in the Vero cell substrate was increased by using a hybrid YF 17D-ZIKV signal sequence for the prM protein. CYZ was highly attenuated both in mice and in human <jats:italic>in vitro<\/jats:italic> models (human neuroblastoma and neuronal progenitor cells), without the need for additional attenuating modifications. It exhibited significantly reduced viral loads in organs compared to a wild-type ZIKV and a complete lack of neuroinvasion following inoculation of immunodeficient A129 mice. A single dose of CYZ elicited high titers of ZIKV-specific neutralizing antibodies in both immunocompetent and A129 mice and protected animals from ZIKV challenge. The data indicate that CYZ is a promising vaccine candidate against ZIKV.<\/jats:p>","DOI":"10.1038\/s41598-018-31375-9","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T17:04:16Z","timestamp":1535562256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine"],"prefix":"10.1038","volume":"8","author":[{"given":"Maryann","family":"Giel-Moloney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Goncalvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Catalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Lecouturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Girerd-Chambaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Maldonado-Arocho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul C.","family":"Gomila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Clotilde","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Oomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Delagrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Burdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Kleanthous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Heinrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin V.","family":"Pugachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"31375_CR1","unstructured":"Monath, T. P. & Heinz, F. X. In Fields Virology (eds Fields, B. N.., Knipe, D. M. & Howley, P. M.) 961\u20131034 (Lippincott-Raven, 1996)."},{"key":"31375_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMp1600297","volume":"374","author":"AS Fauci","year":"2016","unstructured":"Fauci, A. S. & Morens, D. M. Zika Virus in the Americas\u2013Yet Another Arbovirus Threat. N Engl J Med 374, 601\u2013604, https:\/\/doi.org\/10.1056\/NEJMp1600297 (2016).","journal-title":"N Engl J Med"},{"key":"31375_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QCO.0000000000000414","volume":"31","author":"PS Mead","year":"2018","unstructured":"Mead, P. S., Hills, S. L. & Brooks, J. T. Zika virus as a sexually transmitted pathogen. Curr Opin Infect Dis 31, 39\u201344, https:\/\/doi.org\/10.1097\/QCO.0000000000000414 (2018).","journal-title":"Curr Opin Infect Dis"},{"key":"31375_CR4","unstructured":"Epidemiological Update: Neurological syndrome, congenital anomalies and Zika virus infection. (Washington, D.C., 2016)."},{"key":"31375_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/14760584.2017.1345309","volume":"16","author":"A Durbin","year":"2017","unstructured":"Durbin, A. & Wilder-Smith, A. An update on Zika vaccine developments. Expert Rev Vaccines 16, 781\u2013787, https:\/\/doi.org\/10.1080\/14760584.2017.1345309 (2017).","journal-title":"Expert Rev Vaccines"},{"key":"31375_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1126\/science.aaf5316","volume":"352","author":"D Sirohi","year":"2016","unstructured":"Sirohi, D. et al. The 3.8 A resolution cryo-EM structure of Zika virus. Science 352, 467\u2013470, https:\/\/doi.org\/10.1126\/science.aaf5316 (2016).","journal-title":"Science"},{"key":"31375_CR7","unstructured":"Lindenbach, B. D., Thiel, H.-J. & Rice, C. M. In Fields Virology Vol. 1 (eds Knipe, D. M. & Howley, P. M.) Ch. 33, 1101\u20131152 (Wolters Kluwer, 2007)."},{"key":"31375_CR8","unstructured":"Gubler, D., Kuno, G. & Markoff, L. In Fields Virology Vol. 1 (eds Knipe, D. M. & Howley, P. M.) Ch. 34, 1153\u20131252 (Wolters Kluwer, 2007)."},{"key":"31375_CR9","unstructured":"Pugachev, K., Guirakhoo, F., Trent, D. & Monath, T. In New Generation Vaccines (ed. Levine, M. M) 557\u2013569 (CRC Press, 2009)."},{"key":"31375_CR10","doi-asserted-by":"crossref","unstructured":"Monath, T. P., Gershman, M., Erin Staples, J. & Barrett, A. D. T. In Vaccines (eds Plotkin, S. A., Orenstein, W. A. & Offit, P. A.) 870\u2013968 (Elsevier Saunders, 2013).","DOI":"10.1016\/B978-1-4557-0090-5.00043-4"},{"key":"31375_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","volume":"28","author":"B Guy","year":"2010","unstructured":"Guy, B. et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28, 632\u2013649, https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.098 (2010).","journal-title":"Vaccine"},{"key":"31375_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","volume":"372","author":"L Villar","year":"2015","unstructured":"Villar, L. et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372, 113\u2013123, https:\/\/doi.org\/10.1056\/NEJMoa1411037 (2015).","journal-title":"N Engl J Med"},{"key":"31375_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474\u2013478, https:\/\/doi.org\/10.1038\/nature18952 (2016).","journal-title":"Nature"},{"key":"31375_CR14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","volume":"353","author":"P Abbink","year":"2016","unstructured":"Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129\u20131132, https:\/\/doi.org\/10.1126\/science.aah6157 (2016).","journal-title":"Science"},{"key":"31375_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","volume":"391","author":"K Modjarrad","year":"2018","unstructured":"Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391, 563\u2013571, https:\/\/doi.org\/10.1016\/S0140-6736(17)33106-9 (2018).","journal-title":"Lancet"},{"key":"31375_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nm.4322","volume":"23","author":"C Shan","year":"2017","unstructured":"Shan, C. et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat Med 23, 763\u2013767, https:\/\/doi.org\/10.1038\/nm.4322 (2017).","journal-title":"Nat Med"},{"key":"31375_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02975-w","volume":"9","author":"XF Li","year":"2018","unstructured":"Li, X. F. et al. Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. Nat Commun 9, 673, https:\/\/doi.org\/10.1038\/s41467-018-02975-w (2018).","journal-title":"Nat Commun"},{"key":"31375_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/10635150390235520","volume":"52","author":"S Guindon","year":"2003","unstructured":"Guindon, S. & Gascuel, O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52, 696\u2013704, https:\/\/doi.org\/10.1080\/10635150390235520 (2003).","journal-title":"Syst Biol"},{"key":"31375_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jmb.2004.05.028","volume":"340","author":"JD Bendtsen","year":"2004","unstructured":"Bendtsen, J. D., Nielsen, H., von Heijne, G. & Brunak, S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 340, 783\u2013795, https:\/\/doi.org\/10.1016\/j.jmb.2004.05.028 (2004).","journal-title":"J Mol Biol"},{"key":"31375_CR20","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1128\/JVI.72.3.2141-2149.1998","volume":"72","author":"CE Stocks","year":"1998","unstructured":"Stocks, C. E. & Lobigs, M. Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM. J Virol 72, 2141\u20132149 (1998).","journal-title":"J Virol"},{"key":"31375_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/JVI.74.1.24-32.2000","volume":"74","author":"E Lee","year":"2000","unstructured":"Lee, E., Stocks, C. E., Amberg, S. M., Rice, C. M. & Lobigs, M. Mutagenesis of the Signal Sequence of Yellow Fever Virus prM Protein: Enhancement of Signalase Cleavage In Vitro Is Lethal for Virus Production. Journal of Virology 74, 24\u201332, https:\/\/doi.org\/10.1128\/jvi.74.1.24-32.2000 (2000).","journal-title":"Journal of Virology"},{"key":"31375_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1128\/JVI.78.1.178-186.2004","volume":"78","author":"M Lobigs","year":"2003","unstructured":"Lobigs, M. & Lee, E. Inefficient Signalase Cleavage Promotes Efficient Nucleocapsid Incorporation into Budding Flavivirus Membranes. Journal of Virology 78, 178\u2013186, https:\/\/doi.org\/10.1128\/jvi.78.1.178-186.2004 (2003).","journal-title":"Journal of Virology"},{"key":"31375_CR23","doi-asserted-by":"publisher","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","volume":"78","author":"J Arroyo","year":"2004","unstructured":"Arroyo, J. et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78, 12497\u201312507, https:\/\/doi.org\/10.1128\/JVI.78.22.12497-12507.2004 (2004).","journal-title":"J Virol"},{"key":"31375_CR24","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.1073\/pnas.0601932103","volume":"103","author":"TP Monath","year":"2006","unstructured":"Monath, T. P. et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103, 6694\u20136699, https:\/\/doi.org\/10.1073\/pnas.0601932103 (2006).","journal-title":"Proc Natl Acad Sci USA"},{"key":"31375_CR25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.vaccine.2009.10.112","volume":"28","author":"MC Whiteman","year":"2010","unstructured":"Whiteman, M. C. et al. Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine 28, 1075\u20131083, https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.112 (2010).","journal-title":"Vaccine"},{"key":"31375_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1086\/427780","volume":"191","author":"AP Durbin","year":"2005","unstructured":"Durbin, A. P. et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 191, 710\u2013718, https:\/\/doi.org\/10.1086\/427780 (2005).","journal-title":"J Infect Dis"},{"key":"31375_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/infdis\/jiw501","volume":"215","author":"KK Pierce","year":"2017","unstructured":"Pierce, K. K. et al. A Live Attenuated Chimeric West Nile Virus Vaccine, rWN\/DEN4Delta30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. J Infect Dis 215, 52\u201355, https:\/\/doi.org\/10.1093\/infdis\/jiw501 (2017).","journal-title":"J Infect Dis"},{"key":"31375_CR28","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/JVI.72.3.2132-2140.1998","volume":"72","author":"CW Mandl","year":"1998","unstructured":"Mandl, C. W. et al. Spontaneous and engineered deletions in the 3\u2032 noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus. J Virol 72, 2132\u20132140 (1998).","journal-title":"J Virol"},{"key":"31375_CR29","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1128\/JVI.76.7.3534-3543.2002","volume":"76","author":"RM Kofler","year":"2002","unstructured":"Kofler, R. M., Heinz, F. X. & Mandl, C. W. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence. J Virol 76, 3534\u20133543 (2002).","journal-title":"J Virol"},{"key":"31375_CR30","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.celrep.2017.10.016","volume":"21","author":"CR Fontes-Garfias","year":"2017","unstructured":"Fontes-Garfias, C. R. et al. Functional Analysis of Glycosylation of Zika Virus Envelope Protein. Cell Rep 21, 1180\u20131190, https:\/\/doi.org\/10.1016\/j.celrep.2017.10.016 (2017).","journal-title":"Cell Rep"},{"key":"31375_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.biologicals.2005.03.009","volume":"33","author":"TP Monath","year":"2005","unstructured":"Monath, T. P. et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 33, 131\u2013144, https:\/\/doi.org\/10.1016\/j.biologicals.2005.03.009 (2005).","journal-title":"Biologicals"},{"key":"31375_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1006\/viro.1999.9695","volume":"257","author":"F Guirakhoo","year":"1999","unstructured":"Guirakhoo, F. et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257, 363\u2013372, https:\/\/doi.org\/10.1006\/viro.1999.9695 (1999).","journal-title":"Virology"},{"key":"31375_CR33","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4269\/ajtmh.16-0111","volume":"94","author":"SL Rossi","year":"2016","unstructured":"Rossi, S. L. et al. Characterization of a Novel Murine Model to Study Zika Virus. Am J Trop Med Hyg 94, 1362\u20131369, https:\/\/doi.org\/10.4269\/ajtmh.16-0111 (2016).","journal-title":"Am J Trop Med Hyg"},{"key":"31375_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00737-8","volume":"8","author":"C Shan","year":"2017","unstructured":"Shan, C. et al. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nat Commun 8, 676, https:\/\/doi.org\/10.1038\/s41467-017-00737-8 (2017).","journal-title":"Nat Commun"},{"key":"31375_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0035-9203(52)90043-6","volume":"46","author":"GW Dick","year":"1952","unstructured":"Dick, G. W. Zika virus. II. Pathogenicity and physical properties. Trans R Soc Trop Med Hyg 46, 521\u2013534, https:\/\/doi.org\/10.1016\/0035-9203(52)90043-6 (1952).","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"31375_CR36","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1128\/JVI.80.3.1427-1439.2006","volume":"80","author":"AA Rumyantsev","year":"2006","unstructured":"Rumyantsev, A. A., Murphy, B. R. & Pletnev, A. G. A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice. J Virol 80, 1427\u20131439, https:\/\/doi.org\/10.1128\/JVI.80.3.1427-1439.2006 (2006).","journal-title":"J Virol"},{"key":"31375_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.vaccine.2005.07.067","volume":"24","author":"AA Rumyantsev","year":"2006","unstructured":"Rumyantsev, A. A., Chanock, R. M., Murphy, B. R. & Pletnev, A. G. Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys. Vaccine 24, 133\u2013143, https:\/\/doi.org\/10.1016\/j.vaccine.2005.07.067 (2006).","journal-title":"Vaccine"},{"key":"31375_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.stem.2016.04.014","volume":"19","author":"J Dang","year":"2016","unstructured":"Dang, J. et al. Zika Virus Depletes Neural Progenitors in Human Cerebral Organoids through Activation of the Innate Immune Receptor TLR3. Cell Stem Cell 19, 258\u2013265, https:\/\/doi.org\/10.1016\/j.stem.2016.04.014 (2016).","journal-title":"Cell Stem Cell"},{"key":"31375_CR39","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.celrep.2016.05.075","volume":"15","author":"NW Hanners","year":"2016","unstructured":"Hanners, N. W. et al. Western Zika Virus in Human Fetal Neural Progenitors Persists Long Term with Partial Cytopathic and Limited Immunogenic Effects. Cell Rep 15, 2315\u20132322, https:\/\/doi.org\/10.1016\/j.celrep.2016.05.075 (2016).","journal-title":"Cell Rep"},{"key":"31375_CR40","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.aaf6116","volume":"352","author":"PP Garcez","year":"2016","unstructured":"Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816\u2013818, https:\/\/doi.org\/10.1126\/science.aaf6116 (2016).","journal-title":"Science"},{"key":"31375_CR41","doi-asserted-by":"publisher","first-page":"e0004682","DOI":"10.1371\/journal.pntd.0004682","volume":"10","author":"MT Aliota","year":"2016","unstructured":"Aliota, M. T. et al. Characterization of Lethal Zika Virus Infection in AG129 Mice. PLoS Negl Trop Dis 10, e0004682, https:\/\/doi.org\/10.1371\/journal.pntd.0004682 (2016).","journal-title":"PLoS Negl Trop Dis"},{"key":"31375_CR42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.chom.2016.03.010","volume":"19","author":"HM Lazear","year":"2016","unstructured":"Lazear, H. M. et al. A Mouse Model of Zika Virus Pathogenesis. Cell Host Microbe 19, 720\u2013730, https:\/\/doi.org\/10.1016\/j.chom.2016.03.010 (2016).","journal-title":"Cell Host Microbe"},{"key":"31375_CR43","doi-asserted-by":"publisher","first-page":"e1000614","DOI":"10.1371\/journal.ppat.1000614","volume":"5","author":"KC Meier","year":"2009","unstructured":"Meier, K. C., Gardner, C. L., Khoretonenko, M. V., Klimstra, W. B. & Ryman, K. D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 5, e1000614, https:\/\/doi.org\/10.1371\/journal.ppat.1000614 (2009).","journal-title":"PLoS Pathog"},{"key":"31375_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/v4010062","volume":"4","author":"S Zompi","year":"2012","unstructured":"Zompi, S. & Harris, E. Animal models of dengue virus infection. Viruses 4, 62\u201382, https:\/\/doi.org\/10.3390\/v4010062 (2012).","journal-title":"Viruses"},{"key":"31375_CR45","doi-asserted-by":"publisher","first-page":"10532","DOI":"10.1073\/pnas.89.21.10532","volume":"89","author":"AG Pletnev","year":"1992","unstructured":"Pletnev, A. G., Bray, M., Huggins, J. & Lai, C. J. Construction and characterization of chimeric tick-borne encephalitis\/dengue type 4 viruses. Proc Natl Acad Sci USA 89, 10532\u201310536, https:\/\/doi.org\/10.1073\/pnas.89.21.10532 (1992).","journal-title":"Proc Natl Acad Sci USA"},{"key":"31375_CR46","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMcibr1701402","volume":"376","author":"SJ Thomas","year":"2017","unstructured":"Thomas, S. J. Zika Virus Vaccines - A Full Field and Looking for the Closers. N Engl J Med 376, 1883\u20131886, https:\/\/doi.org\/10.1056\/NEJMcibr1701402 (2017).","journal-title":"N Engl J Med"},{"key":"31375_CR47","doi-asserted-by":"publisher","first-page":"e1006487","DOI":"10.1371\/journal.ppat.1006487","volume":"13","author":"MK McCracken","year":"2017","unstructured":"McCracken, M. K. et al. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. Plos Pathog 13, e1006487, https:\/\/doi.org\/10.1371\/journal.ppat.1006487 (2017).","journal-title":"Plos Pathog"},{"key":"31375_CR48","doi-asserted-by":"publisher","first-page":"13103","DOI":"10.1073\/pnas.1306245110","volume":"110","author":"AA Rumyantsev","year":"2013","unstructured":"Rumyantsev, A. A. et al. Single-dose vaccine against tick-borne encephalitis. Proc Natl Acad Sci USA 110, 13103\u201313108, https:\/\/doi.org\/10.1073\/pnas.1306245110 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"31375_CR49","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1016\/j.vaccine.2011.05.032","volume":"29","author":"AA Rumyantsev","year":"2011","unstructured":"Rumyantsev, A. A. et al. Characterization of the RepliVax platform for replication-defective flavivirus vaccines. Vaccine 29, 5184\u20135194, https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.032 (2011).","journal-title":"Vaccine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31375-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:10:20Z","timestamp":1671613820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31375-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31375"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31375-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"18 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are current or former employees of Sanofi Pasteur and may hold company stock.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13206"}}